Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:22 AM
Ignite Modification Date:
2025-12-25 @ 12:22 AM
NCT ID:
NCT01371058
Eligibility Criteria:
Inclusion Criteria:
* Patients with coronary heart disease and had received coronary stenting
* high on-treatment platelet reactivity defined as an ADP-induced platelet aggregation (by LTA)\> 65% at 24 hr after clopidogrel loading (300 \~ 600mg)or 5 days after maintenance dose treatment (75mg / d)
* Informed Consent
Exclusion Criteria:
* receiving GP IIb / IIIa receptor antagonist treatment within 24h before enrollment
* using cilostazol within 7d before enrollment
* aspirin, clopidogrel or policosanol allergies
* NYHA grade III \~ IV
* planned elective coronary revascularization for multivessel coronary artery disease
* long term warfarin treatment after persistent atrial fibrillation, valve surgery or other circumstance
* Severe liver or kidney dysfunction
* Active ulcer or a history of recent gastrointestinal bleeding
* History of coagulation disorder, or recent history of active bleeding
* history of intracranial hemorrhage within 6 months
* Pregnancy
* LDL less than 70mg/dL
* Severe systemic diseases with life expectancy less than 1 year
* planned surgery within next 6 months
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT01371058
Study Brief:
Protocol Section:
NCT01371058